首页 > 最新文献

Advanced pharmaceutical bulletin最新文献

英文 中文
Menadione Sodium Bisulfite Loaded Rhamnolipid Based Solid Lipid Nanoparticle as Skin Lightener Formulation: A Green Production Beside In Vitro/In Vivo Safety Index Evaluation. 作为皮肤增白剂配方的亚硫酸氢钠美那二酮负载鼠李糖脂基固体脂质纳米粒子:体外/体内安全指数评估之外的绿色生产。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-06-22 DOI: 10.34172/apb.2024.047
Fatemeh Asadpour Panbehchouleh, Hossein Amani, Majid Saeedi

Purpose: In the current investigation, an ultrasonic approach was performed to produce menadione sodium bisulfite-loaded solid lipid nanoparticles (MSB-SLNs) with rhamnolipid as bio-surfactant, which aimed to increase the dermal delivery and anti-pigmentation effect.

Methods: To achieve optimum delivery for MSB, the impact of the ratio of two surfactants (rhamnolipid: Tween) on nanoparticle attributes and the respective functions were evaluated. In vitro diffusion process, in vitro cytotoxicity assay, determination of melanin content of melanoma cells, L-DOPA auto-oxidation inhibitory test, and skin irritation studies carried out to investigate the suitability of MSB formulation in dermal application.

Results: The optimized nanoparticles showed an average particle size, zeta potential, polydispersity index (PDI), and drug entrapment efficiency of 117.26±1.12 nm, -6.28±0.33 mV, 0.262±0.002, 83.34±0.75% respectively in hydrophilic-lipophilic balance (HLB) of 12. The in vitro diffusion process demonstrated that MSB-SLN gel had a prolonged release pattern. The levels of MSB in the cutaneous layers (52.192±2.730% or 961.59±50.313 μg/cm2 ) and the receiver compartment (23.721±1.803 % or 437.049± 33.236 μg/cm2 ) for the MSB-SLN gel was higher than MSB simple and showed no cutaneous irritancy and toxicity in rats. MSB-SLN inhibited melanin formation and was remarkably higher than free MSB. MSB-SLN inhibited L-3,4- dihydroxyphenylalanine (L-DOPA) auto-oxidation to a greater extent (95.14±1.46%) than MSB solution (72.28±0.83%).

Conclusion: This study's observations revealed that the produced MSB-SLN might be used as a potential nano-vehicle for MSB dermal administration, thereby opening up innovative options for the management of hyper-melanogenesis problems.

目的:本研究采用超声波方法制备了以鼠李糖脂作为生物表面活性剂的亚硫酸氢钠负载固体脂质纳米颗粒(MSB-SLNs),旨在提高其皮肤递送和抗色素沉着效果:为了实现 MSB 的最佳递送效果,我们评估了两种表面活性剂(鼠李糖脂:吐温)的比例对纳米粒子属性和各自功能的影响。此外,还进行了体外扩散过程、体外细胞毒性试验、黑色素瘤细胞黑色素含量测定、L-DOPA 自氧化抑制试验和皮肤刺激性研究,以考察 MSB 制剂在皮肤应用中的适用性:结果:在亲水-亲油平衡(HLB)为 12 的条件下,优化后的纳米颗粒的平均粒径、ZETA电位、多分散指数(PDI)和药物包埋效率分别为 117.26±1.12 nm、-6.28±0.33 mV、0.262±0.002、83.34±0.75%。体外扩散过程表明,MSB-SLN 凝胶具有延长释放模式。MSB-SLN凝胶在皮肤层(52.192±2.730%或961.59±50.313 μg/cm2)和接收层(23.721±1.803%或437.049±33.236 μg/cm2)的MSB含量高于单纯的MSB,且对大鼠无皮肤刺激性和毒性。MSB-SLN 对黑色素形成的抑制作用明显高于游离 MSB。MSB-SLN 对 L-3,4-二羟基苯丙氨酸(L-DOPA)自身氧化的抑制率(95.14±1.46%)高于 MSB 溶液(72.28±0.83%):本研究的观察结果表明,制备的 MSB-SLN 可用作 MSB 皮肤给药的潜在纳米载体,从而为治疗过度黑色素生成问题提供了创新选择。
{"title":"Menadione Sodium Bisulfite Loaded Rhamnolipid Based Solid Lipid Nanoparticle as Skin Lightener Formulation: A Green Production Beside In Vitro/In Vivo Safety Index Evaluation.","authors":"Fatemeh Asadpour Panbehchouleh, Hossein Amani, Majid Saeedi","doi":"10.34172/apb.2024.047","DOIUrl":"10.34172/apb.2024.047","url":null,"abstract":"<p><strong>Purpose: </strong>In the current investigation, an ultrasonic approach was performed to produce menadione sodium bisulfite-loaded solid lipid nanoparticles (MSB-SLNs) with rhamnolipid as bio-surfactant, which aimed to increase the dermal delivery and anti-pigmentation effect.</p><p><strong>Methods: </strong>To achieve optimum delivery for MSB, the impact of the ratio of two surfactants (rhamnolipid: Tween) on nanoparticle attributes and the respective functions were evaluated. In vitro diffusion process, in vitro cytotoxicity assay, determination of melanin content of melanoma cells, L-DOPA auto-oxidation inhibitory test, and skin irritation studies carried out to investigate the suitability of MSB formulation in dermal application.</p><p><strong>Results: </strong>The optimized nanoparticles showed an average particle size, zeta potential, polydispersity index (PDI), and drug entrapment efficiency of 117.26±1.12 nm, -6.28±0.33 mV, 0.262±0.002, 83.34±0.75% respectively in hydrophilic-lipophilic balance (HLB) of 12. The in vitro diffusion process demonstrated that MSB-SLN gel had a prolonged release pattern. The levels of MSB in the cutaneous layers (52.192±2.730% or 961.59±50.313 μg/cm<sup>2</sup> ) and the receiver compartment (23.721±1.803 % or 437.049± 33.236 μg/cm<sup>2</sup> ) for the MSB-SLN gel was higher than MSB simple and showed no cutaneous irritancy and toxicity in rats. MSB-SLN inhibited melanin formation and was remarkably higher than free MSB. MSB-SLN inhibited L-3,4- dihydroxyphenylalanine (L-DOPA) auto-oxidation to a greater extent (95.14±1.46%) than MSB solution (72.28±0.83%).</p><p><strong>Conclusion: </strong>This study's observations revealed that the produced MSB-SLN might be used as a potential nano-vehicle for MSB dermal administration, thereby opening up innovative options for the management of hyper-melanogenesis problems.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating Functional and Folding Stability of an Engineered E. coli L-asparaginase Harboring Y176F/S241C Mutations. 研究携带 Y176F/S241C 突变的大肠杆菌 L-天冬酰胺酶的功能和折叠稳定性。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-06-22 DOI: 10.34172/apb.2024.048
Mahrokh Dastmalchi, Maryam Hamzeh-Mivehroud, Hassan Rezazadeh, Mohammad M Farajollahi, Siavoush Dastmalchi

Purpose: L-asparaginase has been widely recognized as a critical component in the treatment of various types of lymphoproliferative disorders, since its introduction in 1960s. However, its use in some cases leads to allergic reactions rendering the continuation of treatment unfeasible. Thus, the development of L-asparaginase from alternative sources or the production of engineered enzymes have always been considered. This study aimed to produce and evaluate a novel enzyme designed based on the sequence of L-asparaginase from Escherichia coli bacteria with Y176F/S241C mutations.

Methods: The Y176F/S241C mutant L-asparaginase was successfully expressed as the GST-fusion protein in E. coli, and then was subjected to affinity and size exclusion chromatography. The activity of the purified enzyme was determined based on the released ammonia as the result of substrate hydrolysis using Nessler's reagent. Chemical denaturation experiment in the presence of increasing concentration of guanidinium chloride was applied to determine the folding stability of the purified enzyme.

Results: The mutant enzyme was purified with an efficiency of 77-fold but at a low recovery of 0.7%. The determined kinetic parameters Km, Vmax, kcat, specific activity and catalytic efficiency were 13.96 (mM), 2.218 (mM/min), 273.9 (min-1), 237.8 (IU/mg) and 19.62 (mM-1 min-1), respectively. Moreover, unfolding free energy determined by guanidinium chloride induced denaturation for mutated and commercial L-asparaginase enzymes were 8421 J/mol and 5274 J/mol, respectively.

Conclusion: The mutant enzyme showed improved stability over the wild-type. Although the expression level and recovery were low, the mutant L-asparaginase demonstrated promising activity and stability, with potential clinical and industrial applications.

目的:L-天冬酰胺酶自 20 世纪 60 年代问世以来,已被广泛认为是治疗各类淋巴组织增生性疾病的关键成分。然而,在某些病例中使用 L-天冬酰胺酶会导致过敏反应,从而无法继续治疗。因此,人们一直在考虑从其他来源开发 L-天冬酰胺酶或生产工程酶。本研究旨在生产和评估一种新型酶,该酶是根据大肠杆菌的 L-天冬酰胺酶序列设计的,具有 Y176F/S241C 突变:方法:将Y176F/S241C突变的L-天冬酰胺酶在大肠杆菌中成功表达为GST融合蛋白,并进行亲和层析和尺寸排阻层析。纯化后的酶的活性是根据使用奈斯勒试剂水解底物所释放的氨来测定的。在氯化胍浓度增加的情况下进行化学变性实验,以确定纯化酶的折叠稳定性:结果:突变体酶的纯化效率为 77 倍,但回收率较低,仅为 0.7%。测定的动力学参数 Km、Vmax、kcat、比活度和催化效率分别为 13.96 (mM)、2.218 (mM/min)、273.9 (min-1)、237.8 (IU/mg) 和 19.62 (mM-1 min-1)。此外,用氯化胍诱导变性法测定突变体和商用 L-天冬酰胺酶的解折自由能分别为 8421 J/mol 和 5274 J/mol:结论:与野生型相比,突变型酶的稳定性有所提高。尽管表达水平和恢复能力较低,但突变型 L-天冬酰胺酶表现出了良好的活性和稳定性,具有潜在的临床和工业应用前景。
{"title":"Investigating Functional and Folding Stability of an Engineered <i>E. coli</i> L-asparaginase Harboring Y176F/S241C Mutations.","authors":"Mahrokh Dastmalchi, Maryam Hamzeh-Mivehroud, Hassan Rezazadeh, Mohammad M Farajollahi, Siavoush Dastmalchi","doi":"10.34172/apb.2024.048","DOIUrl":"10.34172/apb.2024.048","url":null,"abstract":"<p><strong>Purpose: </strong>L-asparaginase has been widely recognized as a critical component in the treatment of various types of lymphoproliferative disorders, since its introduction in 1960s. However, its use in some cases leads to allergic reactions rendering the continuation of treatment unfeasible. Thus, the development of L-asparaginase from alternative sources or the production of engineered enzymes have always been considered. This study aimed to produce and evaluate a novel enzyme designed based on the sequence of L-asparaginase from <i>Escherichia coli</i> bacteria with Y176F/S241C mutations.</p><p><strong>Methods: </strong>The Y176F/S241C mutant L-asparaginase was successfully expressed as the GST-fusion protein in <i>E. coli</i>, and then was subjected to affinity and size exclusion chromatography. The activity of the purified enzyme was determined based on the released ammonia as the result of substrate hydrolysis using Nessler's reagent. Chemical denaturation experiment in the presence of increasing concentration of guanidinium chloride was applied to determine the folding stability of the purified enzyme.</p><p><strong>Results: </strong>The mutant enzyme was purified with an efficiency of 77-fold but at a low recovery of 0.7%. The determined kinetic parameters Km, Vmax, kcat, specific activity and catalytic efficiency were 13.96 (mM), 2.218 (mM/min), 273.9 (min<sup>-1</sup>), 237.8 (IU/mg) and 19.62 (mM<sup>-1</sup> min<sup>-1</sup>), respectively. Moreover, unfolding free energy determined by guanidinium chloride induced denaturation for mutated and commercial L-asparaginase enzymes were 8421 J/mol and 5274 J/mol, respectively.</p><p><strong>Conclusion: </strong>The mutant enzyme showed improved stability over the wild-type. Although the expression level and recovery were low, the mutant L-asparaginase demonstrated promising activity and stability, with potential clinical and industrial applications.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities. 利用脂质纳米粒子治疗肝癌的纳米医学策略:探索信号通路和治疗模式。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-07-31 DOI: 10.34172/apb.2024.061
Fereshteh Asgharzadeh, Maryam Moradi Binabaj, Sahar Fanoudi, William C Cho, Yu-Jeong Yang, Maryam Azarian, Mehdi Shafiee Ardestani, Nasim Nasiri, Marzieh Ramezani Farani, Yun Suk Huh

Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.

肝癌,特别是肝细胞癌(HCC),是继胰腺癌之后导致癌症相关死亡的第二大原因。HCC 的 5 年总生存率仍然相对较低。目前,HCC 有多种治疗方法可供选择,包括全身用药、局部微创疗法(如射频消融、经动脉化疗栓塞(TACE)和动脉放射栓塞(TARE)),以及外科干预(如肝切除或移植)。然而,由于癌变肝脏的病理生理变化,向该器官给药的有效性受到了阻碍。为了应对这一挑战,脂基纳米颗粒(LNPs)已成为一种很有前景的平台,可用于递送各种治疗药物。LNPs 具有各种结构配置,可增强其物理稳定性,使其能够容纳具有不同机械性能和疏水性的不同类型的货物。在本文中,我们全面综述了目前 LNPs 在开发抗肝癌疗法中的应用。通过审查现有研究,我们旨在阐明这一领域未来的潜在方向和进展。
{"title":"Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities.","authors":"Fereshteh Asgharzadeh, Maryam Moradi Binabaj, Sahar Fanoudi, William C Cho, Yu-Jeong Yang, Maryam Azarian, Mehdi Shafiee Ardestani, Nasim Nasiri, Marzieh Ramezani Farani, Yun Suk Huh","doi":"10.34172/apb.2024.061","DOIUrl":"10.34172/apb.2024.061","url":null,"abstract":"<p><p>Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths, following pancreatic cancer. The 5-year overall survival rate for HCC remains relatively low. Currently, there are multiple treatment options available for HCC, including systemic drugs, minimally invasive local therapies such as radiofrequency ablation, transarterial chemoembolization (TACE), and arterial radioembolization (TARE), as well as surgical interventions like liver resection or transplantation. However, the effectiveness of drug delivery to the cancerous liver is hindered by pathophysiological changes in the organ. In order to address this challenge, lipid-based nanoparticles (LNPs) have emerged as promising platforms for delivering a diverse range of therapeutic drugs. LNPs offer various structural configurations that enhance their physical stability and enable them to accommodate different types of cargo with varying mechanical properties and degrees of hydrophobicity. In this article, we provide a comprehensive review of the current applications of LNPs in the development of anti-HCC therapies. By examining the existing research, we aim to shed light on the potential future directions and advancements in this field.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-stage Acting Dendrimeric Nanoparticle for Deepened Chemotherapeutic Drug Delivery to Tumor Cells. 双级作用树枝状聚合物纳米粒子用于加深对肿瘤细胞的化疗药物输送。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-06-29 DOI: 10.34172/apb.2024.054
Mohammad Shahpouri, Mohammad Amin Adili-Aghdam, Hossein Mahmudi, Saeedeh Ghiasvand, Hamed Dadashi, Aysan Salemi, Sajjad Alimohammadvand, Leila Roshangar, Abolfazl Barzegari, Mehdi Jaymand, Rana Jahanban-Esfahlan

Purpose: We report on the design of hypoxia-induced dual-stage acting dendrimeric nanoparticles (NPs) for selective delivery of two chemotherapeutic model drugs doxorubicin (DOX) and tirapazamin (TPZ) for deepened drug delivery into hypoxic tumors in vitro.

Methods: PAMAM G5 dendrimers were crosslinked with a hypoxic azo linker, attached to a mPEG to form a detachable corona on the dendrimer surface (PAP NPs). NPs were characterized by Zeta sizer, transmission electron microscope (TEM), Fourier transforms infrared (FTIR) and drug release kinetics. The anti-cancer performance of PAPs was evaluated by numerous tests in 2D and 3D cultured MDA-MB-231 breast cancer cells.

Results: MTT assay showed a significant difference between PAP and PAMAMG5 in terms of biocompatibility, and the effect of PAP@DOX was significantly greater than free DOX in hypoxic conditions. The results of DAPI and Annexin V-FITC/PI cell staining also confirmed uniform drug penetration as validated by induction of 90% cell apoptosis in spheroids and a high level of PAP@DOX-induced ROS generation under hypoxia conditions. Mechanistically, PAP@DOX significantly reduced the expression of mTOR, and Notch1, while the expression of Bax and Caspase3 was considerably unregulated, compared to the controls. Importantly, hypoxia-responsive disintegration and hypoxia-induced activation of HAP drug were synergized to promote deep and homogenous HAP distribution in whole microtumor regions to efficiently eliminate residual tumor cells.

Conclusion: Our results indicate the safety and high therapeutic potential of PAP system for targeted drug delivery of chemotherapeutics in particular HAPs which show maximum anti-cancer activity against hypoxic solid tumors.

目的:我们报告了缺氧诱导双级作用树枝状分子纳米颗粒(NPs)的设计,用于体外选择性递送两种化疗模型药物多柔比星(DOX)和替拉帕嗪(TPZ),以加深缺氧肿瘤的药物递送:方法:PAMAM G5树枝状聚合物与低氧偶氮连接剂交联,并与mPEG连接,在树枝状聚合物表面形成可分离的电晕(PAP NPs)。研究人员通过 Zeta 分析仪、透射电子显微镜(TEM)、傅立叶变换红外光谱(FTIR)和药物释放动力学对 NPs 进行了表征。通过在二维和三维培养的 MDA-MB-231 乳腺癌细胞中进行多项测试,评估了 PAPs 的抗癌性能:MTT试验表明,PAP与PAMAMG5在生物相容性方面存在显著差异,在缺氧条件下,PAP@DOX的效果明显高于游离DOX。DAPI和Annexin V-FITC/PI细胞染色结果也证实了药物的均匀渗透,球形细胞中90%的细胞凋亡诱导和缺氧条件下PAP@DOX诱导的高水平ROS生成也验证了这一点。从机理上讲,与对照组相比,PAP@DOX 能明显降低 mTOR 和 Notch1 的表达,而 Bax 和 Caspase3 的表达则明显不受调控。重要的是,缺氧反应性解体和缺氧诱导的HAP药物激活协同作用,促进了HAP在整个微小肿瘤区域的深层和均匀分布,从而有效消除残留的肿瘤细胞:我们的研究结果表明,PAP 系统用于化疗药物的靶向给药具有安全性和高治疗潜力,尤其是 HAPs 对缺氧性实体瘤具有最大的抗癌活性。
{"title":"Dual-stage Acting Dendrimeric Nanoparticle for Deepened Chemotherapeutic Drug Delivery to Tumor Cells.","authors":"Mohammad Shahpouri, Mohammad Amin Adili-Aghdam, Hossein Mahmudi, Saeedeh Ghiasvand, Hamed Dadashi, Aysan Salemi, Sajjad Alimohammadvand, Leila Roshangar, Abolfazl Barzegari, Mehdi Jaymand, Rana Jahanban-Esfahlan","doi":"10.34172/apb.2024.054","DOIUrl":"10.34172/apb.2024.054","url":null,"abstract":"<p><strong>Purpose: </strong>We report on the design of hypoxia-induced dual-stage acting dendrimeric nanoparticles (NPs) for selective delivery of two chemotherapeutic model drugs doxorubicin (DOX) and tirapazamin (TPZ) for deepened drug delivery into hypoxic tumors <i>in vitro</i>.</p><p><strong>Methods: </strong>PAMAM G5 dendrimers were crosslinked with a hypoxic azo linker, attached to a mPEG to form a detachable corona on the dendrimer surface (PAP NPs). NPs were characterized by Zeta sizer, transmission electron microscope (TEM), Fourier transforms infrared (FTIR) and drug release kinetics. The anti-cancer performance of PAPs was evaluated by numerous tests in 2D and 3D cultured MDA-MB-231 breast cancer cells.</p><p><strong>Results: </strong>MTT assay showed a significant difference between PAP and PAMAMG5 in terms of biocompatibility, and the effect of PAP@DOX was significantly greater than free DOX in hypoxic conditions. The results of DAPI and Annexin V-FITC/PI cell staining also confirmed uniform drug penetration as validated by induction of 90% cell apoptosis in spheroids and a high level of PAP@DOX-induced ROS generation under hypoxia conditions. Mechanistically, PAP@DOX significantly reduced the expression of mTOR, and Notch1, while the expression of Bax and Caspase3 was considerably unregulated, compared to the controls. Importantly, hypoxia-responsive disintegration and hypoxia-induced activation of HAP drug were synergized to promote deep and homogenous HAP distribution in whole microtumor regions to efficiently eliminate residual tumor cells.</p><p><strong>Conclusion: </strong>Our results indicate the safety and high therapeutic potential of PAP system for targeted drug delivery of chemotherapeutics in particular HAPs which show maximum anti-cancer activity against hypoxic solid tumors.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Accuracy of Large Language Model (ChatGPT) in Providing Information on Metastatic Breast Cancer. 评估大型语言模型 (ChatGPT) 在提供转移性乳腺癌信息方面的准确性。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-07-31 DOI: 10.34172/apb.2024.060
Ramakrishna Gummadi, Nagasen Dasari, D Sathis Kumar, Sai Kiran S S Pindiprolu

Purpose: Artificial intelligence (AI), particularly large language models like ChatGPT developed by OpenAI, has demonstrated potential in various domains, including medicine. While ChatGPT has shown the capability to pass rigorous exams like the United States Medical Licensing Examination (USMLE) Step 1, its proficiency in addressing breast cancer-related inquiries-a complex and prevalent disease-remains underexplored. This study aims to assess the accuracy and comprehensiveness of ChatGPT's responses to common breast cancer questions, addressing a critical gap in the literature and evaluating its potential in enhancing patient education and support in breast cancer management.

Methods: A curated list of 100 frequently asked breast cancer questions was compiled from Cancer.net, the National Breast Cancer Foundation, and clinical practice. These questions were input into ChatGPT, and the responses were evaluated for accuracy by two primary experts using a four-point scale. Discrepancies in scoring were resolved through additional expert review.

Results: Of the 100 responses, 5 were entirely inaccurate, 22 partially accurate, 42 accurate but lacking comprehensiveness, and 31 highly accurate. The majority of the responses were found to be at least partially accurate, demonstrating ChatGPT's potential in providing reliable information on breast cancer.

Conclusion: ChatGPT shows promise as a supplementary tool for patient education on breast cancer. While generally accurate, the presence of inaccuracies underscores the need for professional oversight. The study advocates for integrating AI tools like ChatGPT in healthcare settings to support patient-provider interactions and health education, emphasizing the importance of regular updates to reflect the latest research and clinical guidelines.

目的:人工智能(AI),尤其是像 OpenAI 开发的 ChatGPT 这样的大型语言模型,已在包括医学在内的各个领域展现出潜力。虽然 ChatGPT 已显示出通过美国医学执业资格考试(USMLE)第 1 步等严格考试的能力,但它在处理乳腺癌相关咨询--一种复杂而普遍的疾病--方面的能力仍未得到充分探索。本研究旨在评估 ChatGPT 对常见乳腺癌问题回答的准确性和全面性,填补文献中的一个重要空白,并评估其在加强患者教育和支持乳腺癌管理方面的潜力:方法:从 Cancer.net、全美乳腺癌基金会和临床实践中整理出 100 个乳腺癌常见问题。这些问题被输入到 ChatGPT 中,并由两位主要专家使用四点量表对回复的准确性进行评估。评分中出现的差异通过额外的专家审核来解决:在 100 个回答中,5 个完全不准确,22 个部分准确,42 个准确但不够全面,31 个高度准确。大多数回复至少部分准确,这表明 ChatGPT 在提供可靠的乳腺癌信息方面具有潜力:结论:ChatGPT 有希望成为乳腺癌患者教育的辅助工具。虽然总体上是准确的,但不准确之处的存在凸显了专业监督的必要性。该研究提倡将 ChatGPT 等人工智能工具整合到医疗环境中,以支持患者与医护人员之间的互动和健康教育,并强调了定期更新以反映最新研究和临床指南的重要性。
{"title":"Evaluating the Accuracy of Large Language Model (ChatGPT) in Providing Information on Metastatic Breast Cancer.","authors":"Ramakrishna Gummadi, Nagasen Dasari, D Sathis Kumar, Sai Kiran S S Pindiprolu","doi":"10.34172/apb.2024.060","DOIUrl":"10.34172/apb.2024.060","url":null,"abstract":"<p><strong>Purpose: </strong>Artificial intelligence (AI), particularly large language models like ChatGPT developed by OpenAI, has demonstrated potential in various domains, including medicine. While ChatGPT has shown the capability to pass rigorous exams like the United States Medical Licensing Examination (USMLE) Step 1, its proficiency in addressing breast cancer-related inquiries-a complex and prevalent disease-remains underexplored. This study aims to assess the accuracy and comprehensiveness of ChatGPT's responses to common breast cancer questions, addressing a critical gap in the literature and evaluating its potential in enhancing patient education and support in breast cancer management.</p><p><strong>Methods: </strong>A curated list of 100 frequently asked breast cancer questions was compiled from Cancer.net, the National Breast Cancer Foundation, and clinical practice. These questions were input into ChatGPT, and the responses were evaluated for accuracy by two primary experts using a four-point scale. Discrepancies in scoring were resolved through additional expert review.</p><p><strong>Results: </strong>Of the 100 responses, 5 were entirely inaccurate, 22 partially accurate, 42 accurate but lacking comprehensiveness, and 31 highly accurate. The majority of the responses were found to be at least partially accurate, demonstrating ChatGPT's potential in providing reliable information on breast cancer.</p><p><strong>Conclusion: </strong>ChatGPT shows promise as a supplementary tool for patient education on breast cancer. While generally accurate, the presence of inaccuracies underscores the need for professional oversight. The study advocates for integrating AI tools like ChatGPT in healthcare settings to support patient-provider interactions and health education, emphasizing the importance of regular updates to reflect the latest research and clinical guidelines.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the Hidden Menace: A Topic Modeling Analysis of Hijacked Medical Journals. 揭开隐藏威胁的面纱:对被劫持医学期刊的主题建模分析。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-01 Epub Date: 2024-03-02 DOI: 10.34172/apb.2024.029
Mehdi Dadkhah, Mihály Hegedűs, Prema Nedungadi, Raghu Raman, Lóránt Dénes Dávid

Purpose: Nowadays, many studies discuss scholarly publishing and associated challenges, but the problem of hijacked journals has been neglected. Hijacked journals are cloned websites that mimic original journals but are managed by cybercriminals. The present study uses a topic modeling approach to analyze published papers in hijacked versions of medical journals.

Methods: A total of 3384 papers were downloaded from 21 hijacked journals in the medical domain and analyzed by topic modeling algorithm.

Results: Results indicate that hijacked versions of medical journals are published in most fields of the medical domain and typically respect the primary domain of the original journal.

Conclusion: The academic world is faced with the third-generation of hijacked journals, and their detection may be more complex than common ones. The usage of artificial intelligence (AI) can be a powerful tool to deal with the phenomenon.

目的:如今,许多研究都在讨论学术出版和相关挑战,但却忽视了期刊被劫持的问题。被劫持期刊是模仿原始期刊的克隆网站,但由网络犯罪分子管理。本研究采用主题建模法分析被劫持版医学期刊上发表的论文:方法:从医学领域的 21 种被劫持期刊中下载了共计 3384 篇论文,并通过主题建模算法进行分析:结果表明,被劫持的医学期刊发表的论文涉及医学领域的大部分领域,并且通常尊重原期刊的主要领域:结论:学术界面临着第三代劫持期刊,对它们的检测可能比普通期刊更复杂。使用人工智能(AI)是应对这一现象的有力工具。
{"title":"Unveiling the Hidden Menace: A Topic Modeling Analysis of Hijacked Medical Journals.","authors":"Mehdi Dadkhah, Mihály Hegedűs, Prema Nedungadi, Raghu Raman, Lóránt Dénes Dávid","doi":"10.34172/apb.2024.029","DOIUrl":"10.34172/apb.2024.029","url":null,"abstract":"<p><strong>Purpose: </strong>Nowadays, many studies discuss scholarly publishing and associated challenges, but the problem of hijacked journals has been neglected. Hijacked journals are cloned websites that mimic original journals but are managed by cybercriminals. The present study uses a topic modeling approach to analyze published papers in hijacked versions of medical journals.</p><p><strong>Methods: </strong>A total of 3384 papers were downloaded from 21 hijacked journals in the medical domain and analyzed by topic modeling algorithm.</p><p><strong>Results: </strong>Results indicate that hijacked versions of medical journals are published in most fields of the medical domain and typically respect the primary domain of the original journal.</p><p><strong>Conclusion: </strong>The academic world is faced with the third-generation of hijacked journals, and their detection may be more complex than common ones. The usage of artificial intelligence (AI) can be a powerful tool to deal with the phenomenon.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Hybrid Nanocarriers as Co-delivery Systems for Enhanced Cancer Therapy 作为辅助给药系统的靶向混合纳米载体可增强癌症治疗效果
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-05-15 DOI: 10.34172/apb.2024.046
Joan Onyebuchi Erebor, Elizabeth Oladoyin Agboluaje, Ava M Perkins, Megha Krishnakumar, N. Ngwuluka
Hybrid nanocarriers have realized a growing interest in drug delivery research because of the potential of being able to treat, manage or cure diseases that previously had limited therapy or cure. Cancer is currently considered the second leading cause of death globally. This makes cancer therapy a major focus in terms of the need for efficacious and safe drug formulations that can be used to reduce the rate of morbidity and mortality globally. The major challenge encountered over the years with cancer chemotherapy is the non-selectivity of anticancer drugs, leading to severe adverse effects in patients. Multidrug resistance has also resulted in treatment failure in cancer chemotherapy over the years. Hybrid nanocarriers can be targeted to the site and offer co-delivery of two or more chemotherapeutics, thus leading to synergistic or additive results. This makes hybrid nanocarriers an extremely attractive type of drug delivery system for cancer therapy. Hybrid nanocarrier systems are also attracting attention as possible non-viral gene vectors that could have a higher level of transfection, and be efficacious, with the added advantage of being safer than viral vectors in clinical settings. An extensive review of various aspects of hybrid nanocarriers was discussed in this paper. It is envisaged that in the future, metastatic cancers, multi-drug resistant cancers, and low prognosis cancers like pancreatic cancers, will have a lasting solution via hybrid nanocarrier formulations with targeted co-delivery of therapeutics.
由于混合纳米载体具有治疗、控制或治愈以往治疗或治愈效果有限的疾病的潜力,因此在药物输送研究领域的兴趣日益浓厚。癌症目前被认为是全球第二大死因。因此,癌症治疗成为人们关注的焦点,人们需要高效、安全的药物制剂来降低全球的发病率和死亡率。多年来,癌症化疗面临的主要挑战是抗癌药物的非选择性,从而导致患者出现严重的不良反应。多年来,多药耐药性也导致了癌症化疗的失败。混合纳米载体可以靶向治疗部位,提供两种或两种以上化疗药物的联合给药,从而产生协同或相加的效果。这使得混合纳米载体成为一种极具吸引力的癌症治疗药物输送系统。混合纳米载体系统作为一种可能的非病毒基因载体也备受关注,因为这种载体可以实现更高水平的转染和疗效,而且在临床环境中比病毒载体更安全。本文广泛综述了混合纳米载体的各个方面。预计在未来,转移性癌症、多重耐药性癌症和预后较差的癌症(如胰腺癌)将可通过混合纳米载体制剂与靶向联合给药疗法得到持久的解决。
{"title":"Targeted Hybrid Nanocarriers as Co-delivery Systems for Enhanced Cancer Therapy","authors":"Joan Onyebuchi Erebor, Elizabeth Oladoyin Agboluaje, Ava M Perkins, Megha Krishnakumar, N. Ngwuluka","doi":"10.34172/apb.2024.046","DOIUrl":"https://doi.org/10.34172/apb.2024.046","url":null,"abstract":"Hybrid nanocarriers have realized a growing interest in drug delivery research because of the potential of being able to treat, manage or cure diseases that previously had limited therapy or cure. Cancer is currently considered the second leading cause of death globally. This makes cancer therapy a major focus in terms of the need for efficacious and safe drug formulations that can be used to reduce the rate of morbidity and mortality globally. The major challenge encountered over the years with cancer chemotherapy is the non-selectivity of anticancer drugs, leading to severe adverse effects in patients. Multidrug resistance has also resulted in treatment failure in cancer chemotherapy over the years. Hybrid nanocarriers can be targeted to the site and offer co-delivery of two or more chemotherapeutics, thus leading to synergistic or additive results. This makes hybrid nanocarriers an extremely attractive type of drug delivery system for cancer therapy. Hybrid nanocarrier systems are also attracting attention as possible non-viral gene vectors that could have a higher level of transfection, and be efficacious, with the added advantage of being safer than viral vectors in clinical settings. An extensive review of various aspects of hybrid nanocarriers was discussed in this paper. It is envisaged that in the future, metastatic cancers, multi-drug resistant cancers, and low prognosis cancers like pancreatic cancers, will have a lasting solution via hybrid nanocarrier formulations with targeted co-delivery of therapeutics.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140974974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking Therapeutic Potential: Enhanced shRNA delivery with Tat peptide in the Human Respiratory Syncytial Virus Treatment 释放治疗潜力:在人类呼吸道合胞病毒治疗中利用 Tat 肽增强 shRNA 递送
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-05-14 DOI: 10.34172/apb.2024.045
Saeid Amiri Zadeh Fard, Haniyeh Abuei, Abbas Behzad Behbahani, Gholamreza Rafiei dehbidi, F. Zare, Maryam Nejabat, Alireza Safarpour, Ali Farhadi
Purpose: This research investigated the development of short hairpin RNA (shRNA) molecules designed to target specific regions of the HRSV M and F genes. The study aimed to assess the therapeutic potential of these shRNAs and evaluate the effectiveness of Tat peptide-mediated delivery in enhancing their functionality. Methods: To investigate the therapeutic potential of short hairpin RNA against HRSV, we acquired isolates from pediatric patients experiencing respiratory illness. These isolates were then cultured in human epidermoid carcinoma cells (HEp-2). To target the M and F genes of HRSV, we constructed plasmids expressing shRNAs. We further investigated the Tat peptide as a facilitator for shRNA plasmid delivery. The cytotoxicity of ribavirin, shRNA constructs, and control agents was assessed using the MTT assay. Next, we compared the transfection efficiency of Tat peptide-mediated shRNA delivery with that of lipofectamine 3000™. Finally, real-time PCR was employed to quantify HRSV replication in the treated cells. Results: Our study successfully demonstrated that Tat peptide-mediated delivery of shRNA plasmids significantly suppressed the expression of the M and F genes of HRSV compared to lipofectamine 3000™. This suppression was evident in both short-term experiments and scenarios involving stable shRNA expression. Furthermore, the combination of ribavirin with shRNA treatment resulted in a substantial reduction in viral load. Notably, the most pronounced antiviral effect was observed when both shRNAs were employed simultaneously. Conclusion: Our findings suggest that Tat peptide-mediated delivery of shRNA plasmids holds significant potential for achieving stable suppression of HRSV genes. This approach warrants further investigation as a potential gene therapy strategy for HRSV. By demonstrating promising results in vitro, this study highlights the need for future in vivo studies to comprehensively evaluate the therapeutic potential of this approach in a clinical setting.
目的:本研究调查了针对 HRSV M 和 F 基因特定区域设计的短发夹 RNA (shRNA) 分子的开发情况。研究旨在评估这些 shRNA 的治疗潜力,并评价 Tat 肽介导的递送在增强其功能方面的有效性。研究方法为了研究短发夹 RNA 对 HRSV 的治疗潜力,我们从患有呼吸道疾病的儿科患者身上获得了分离物。然后将这些分离株培养在人类表皮癌细胞(HEp-2)中。为了靶向 HRSV 的 M 和 F 基因,我们构建了表达 shRNA 的质粒。我们进一步研究了作为 shRNA 质粒递送促进剂的 Tat 肽。我们使用 MTT 试验评估了利巴韦林、shRNA 构建体和对照药剂的细胞毒性。接着,我们比较了 Tat 肽介导的 shRNA 转染效率和脂质体转染胺 3000™ 的转染效率。最后,我们使用实时 PCR 对处理过的细胞中的 HRSV 复制进行了量化。结果我们的研究成功证明,与脂质体转染胺 3000™ 相比,Tat 肽介导的 shRNA 质粒能显著抑制 HRSV M 和 F 基因的表达。这种抑制作用在短期实验和涉及 shRNA 稳定表达的情况下都很明显。此外,利巴韦林与 shRNA 联合治疗可大幅降低病毒载量。值得注意的是,当两种 shRNA 同时使用时,抗病毒效果最为明显。结论我们的研究结果表明,Tat 肽介导的 shRNA 质粒在稳定抑制 HRSV 基因方面具有巨大潜力。作为一种潜在的 HRSV 基因治疗策略,这种方法值得进一步研究。本研究通过在体外展示有前景的结果,强调了未来进行体内研究的必要性,以全面评估这种方法在临床环境中的治疗潜力。
{"title":"Unlocking Therapeutic Potential: Enhanced shRNA delivery with Tat peptide in the Human Respiratory Syncytial Virus Treatment","authors":"Saeid Amiri Zadeh Fard, Haniyeh Abuei, Abbas Behzad Behbahani, Gholamreza Rafiei dehbidi, F. Zare, Maryam Nejabat, Alireza Safarpour, Ali Farhadi","doi":"10.34172/apb.2024.045","DOIUrl":"https://doi.org/10.34172/apb.2024.045","url":null,"abstract":"Purpose: This research investigated the development of short hairpin RNA (shRNA) molecules designed to target specific regions of the HRSV M and F genes. The study aimed to assess the therapeutic potential of these shRNAs and evaluate the effectiveness of Tat peptide-mediated delivery in enhancing their functionality. Methods: To investigate the therapeutic potential of short hairpin RNA against HRSV, we acquired isolates from pediatric patients experiencing respiratory illness. These isolates were then cultured in human epidermoid carcinoma cells (HEp-2). To target the M and F genes of HRSV, we constructed plasmids expressing shRNAs. We further investigated the Tat peptide as a facilitator for shRNA plasmid delivery. The cytotoxicity of ribavirin, shRNA constructs, and control agents was assessed using the MTT assay. Next, we compared the transfection efficiency of Tat peptide-mediated shRNA delivery with that of lipofectamine 3000™. Finally, real-time PCR was employed to quantify HRSV replication in the treated cells. Results: Our study successfully demonstrated that Tat peptide-mediated delivery of shRNA plasmids significantly suppressed the expression of the M and F genes of HRSV compared to lipofectamine 3000™. This suppression was evident in both short-term experiments and scenarios involving stable shRNA expression. Furthermore, the combination of ribavirin with shRNA treatment resulted in a substantial reduction in viral load. Notably, the most pronounced antiviral effect was observed when both shRNAs were employed simultaneously. Conclusion: Our findings suggest that Tat peptide-mediated delivery of shRNA plasmids holds significant potential for achieving stable suppression of HRSV genes. This approach warrants further investigation as a potential gene therapy strategy for HRSV. By demonstrating promising results in vitro, this study highlights the need for future in vivo studies to comprehensively evaluate the therapeutic potential of this approach in a clinical setting.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140979031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Superior Anti-Arrhythmogenic Effect of Combined Conditioning with Nicotinamide Mononucleotide and Ubiquinol in Myocardial Ischemia/Reperfusion Injury in Aged Rats 烟酰胺单核苷酸和泛醌联合调节对老年大鼠心肌缺血/再灌注损伤的卓越抗心律失常作用
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-04-15 DOI: 10.34172/apb.2024.044
Behnaz Mokhtari, Amirhossein Jessri, Samad Ghaffari, R. Badalzadeh
Purpose: Lethal ventricular arrhythmias are a significant clinical concern following reperfusion therapies in elderly patients with myocardial infarction. The combination of multi-target therapies to achieve optimal anti-arrhythmogenesis and improve the chances of successful translation for patient benefit has prompted considerable interest. This study examined the anti-arrhythmic effect of nicotinamide mononucleotide (NMN)/ubiquinol combination treatment following myocardial ischemia/reperfusion (IR) injury in aged rats, with an emphasis on the role of oxidative stress and nitric oxide (NO). Methods: Male Wistar rats (n=30, 22-24 months old, 400-450g) were randomized into five groups with or without IR and/or NMN and ubiquinol, either alone or in combination. NMN (100mg/kg/48hours) was administered intraperitoneally for 28 days before IR, and ubiquinol (30mg/kg) was injected intravenously at early reperfusion. Electrocardiographic signals were recorded during the ischemia and the first 30 minutes of reperfusion. Two hours after reperfusion, myocardial hemodynamic and LDH release were measured, and the left ventricle samples were obtained to evaluate oxidative stress markers and NO levels. Results: NMN/ubiquinol combination treatment significantly minimized the occurrence and severity of IR-induced arrhythmias, improved myocardial function, and reduced LDH release (P<.05). It also decreased MDA content, increased SOD, GPx, and CAT activities, and enhanced NO formation (P<.05). This combined treatment showed greater efficacy than the single treatments. Conclusion: This study revealed the anti-arrhythmic effect of NMN/ubiquinol combination treatment in IR-treated aged rats, which may be associated with reduced oxidative stress and increased NO formation. This combinational approach deserves more investigation due to its potential to confer better anti-arrhythmic effect during aging.
目的:致命性室性心律失常是老年心肌梗死患者接受再灌注疗法后的一个重大临床问题。为达到最佳的抗心律失常效果并提高成功转化为患者获益的机会,多靶点疗法的联合应用引起了广泛关注。本研究考察了烟酰胺单核苷酸(NMN)/泛醌醇联合疗法在老年大鼠心肌缺血/再灌注(IR)损伤后的抗心律失常效果,重点研究了氧化应激和一氧化氮(NO)的作用。研究方法将雄性 Wistar 大鼠(n=30,22-24 个月大,体重 400-450g)随机分为五组,分别单独或联合使用或不使用 IR 和/或 NMN 和泛醌醇。在红外照射前腹腔注射 NMN(100 毫克/千克/48 小时)28 天,在再灌注早期静脉注射泛醌醇(30 毫克/千克)。在缺血和再灌注的前30分钟记录心电图信号。再灌注两小时后,测量心肌血流动力学和LDH释放,并采集左心室样本以评估氧化应激标记物和NO水平。结果NMN/泛醌醇联合治疗可明显减少红外诱发心律失常的发生率和严重程度,改善心肌功能,减少 LDH 释放(P<.05)。它还降低了 MDA 含量,提高了 SOD、GPx 和 CAT 活性,并增强了 NO 的形成(P<.05)。这种联合疗法比单一疗法显示出更大的疗效。结论本研究揭示了 NMN/泛醌醇联合疗法对红外治疗的老年大鼠的抗心律失常作用,这可能与氧化应激减少和 NO 形成增加有关。由于这种联合方法有可能在衰老过程中产生更好的抗心律失常效果,因此值得进一步研究。
{"title":"Superior Anti-Arrhythmogenic Effect of Combined Conditioning with Nicotinamide Mononucleotide and Ubiquinol in Myocardial Ischemia/Reperfusion Injury in Aged Rats","authors":"Behnaz Mokhtari, Amirhossein Jessri, Samad Ghaffari, R. Badalzadeh","doi":"10.34172/apb.2024.044","DOIUrl":"https://doi.org/10.34172/apb.2024.044","url":null,"abstract":"Purpose: Lethal ventricular arrhythmias are a significant clinical concern following reperfusion therapies in elderly patients with myocardial infarction. The combination of multi-target therapies to achieve optimal anti-arrhythmogenesis and improve the chances of successful translation for patient benefit has prompted considerable interest. This study examined the anti-arrhythmic effect of nicotinamide mononucleotide (NMN)/ubiquinol combination treatment following myocardial ischemia/reperfusion (IR) injury in aged rats, with an emphasis on the role of oxidative stress and nitric oxide (NO). Methods: Male Wistar rats (n=30, 22-24 months old, 400-450g) were randomized into five groups with or without IR and/or NMN and ubiquinol, either alone or in combination. NMN (100mg/kg/48hours) was administered intraperitoneally for 28 days before IR, and ubiquinol (30mg/kg) was injected intravenously at early reperfusion. Electrocardiographic signals were recorded during the ischemia and the first 30 minutes of reperfusion. Two hours after reperfusion, myocardial hemodynamic and LDH release were measured, and the left ventricle samples were obtained to evaluate oxidative stress markers and NO levels. Results: NMN/ubiquinol combination treatment significantly minimized the occurrence and severity of IR-induced arrhythmias, improved myocardial function, and reduced LDH release (P<.05). It also decreased MDA content, increased SOD, GPx, and CAT activities, and enhanced NO formation (P<.05). This combined treatment showed greater efficacy than the single treatments. Conclusion: This study revealed the anti-arrhythmic effect of NMN/ubiquinol combination treatment in IR-treated aged rats, which may be associated with reduced oxidative stress and increased NO formation. This combinational approach deserves more investigation due to its potential to confer better anti-arrhythmic effect during aging.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression." 探索一种协同方法:双 GLP-1 激动剂联合 Degludec 基础胰岛素用于 1 型糖尿病早期治疗及其对白蛋白-胰岛素生成细胞表达的影响"。
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-03-18 DOI: 10.34172/apb.2024.040
A. Ahmed, M. Akl
This manuscript explores various aspects related to the use of dual GLP-1 agonist with degludec basal insulin as a potential treatment approach for early type 1 diabetes. The background section highlights the destruction of beta cells in type 1 diabetes and the emergence of GLP-1 agonists as a promising option for managing obesity and type 2 diabetes. The authors discuss a retrospective analysis of the efficacy of semaglutide, a GLP-1 agonist, in patients with newly diagnosed type 1 diabetes. The results show the elimination of prandial and basal insulin, increased C-peptide levels, and improved glycemic control. However, the study's retrospective nature and lack of a control group emphasize the need for larger prospective trials. The interpretation section highlights the potential of GLP-1 agonists in protecting residual beta cells, stimulating cell proliferation, and reprogramming liver cells into insulin-producing cells. Moreover, modifying GLP-1 agonists with albumin ligands shows promise in extending their half-life and enhancing their anti-diabetic effects. The perspective section provides a comprehensive overview of the synergistic approach, considering the pharmacokinetic properties of degludec, the plasticity of adult human hepatic tissue, and the benefits of modified GLP-1 derivatives. The conclusion emphasizes the need for further research to explore the full potential of this approach in type 1 diabetes treatment. The proposed approach offers a promising avenue for the treatment of type 1 diabetes, integrating the autoimmune hypothesis, the proliferative effects of GLP-1, and modifications using albumin ligands. By combining these elements, we can strive towards restoring beta cell mass and function, ultimately improving the lives of individuals living with type 1 diabetes. The manuscript is planned to undergo clinical trials in 2024, registered as 'Amr Ahmed, Maher M. Akl, Semaglutide GLP1 Agonists with Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus' with ClinicalTrials.gov Identifier NCT06057077.
本手稿探讨了与使用双 GLP-1 激动剂和德格鲁德基础胰岛素作为早期 1 型糖尿病潜在治疗方法有关的各个方面。背景部分强调了 1 型糖尿病中β细胞的破坏,以及 GLP-1 激动剂作为控制肥胖和 2 型糖尿病的一种有前途的选择的出现。作者讨论了一项关于 GLP-1 激动剂 semaglutide 对新诊断出的 1 型糖尿病患者疗效的回顾性分析。结果显示,患者餐前和基础胰岛素用量减少,C 肽水平升高,血糖控制得到改善。然而,该研究具有回顾性,且缺乏对照组,因此需要进行更大规模的前瞻性试验。解释部分强调了 GLP-1 激动剂在保护残留β细胞、刺激细胞增殖和将肝细胞重编程为胰岛素分泌细胞方面的潜力。此外,用白蛋白配体修饰 GLP-1 激动剂有望延长其半衰期并增强其抗糖尿病效果。展望部分对协同方法进行了全面概述,考虑了degludec的药代动力学特性、成人肝组织的可塑性以及改良GLP-1衍生物的益处。结论强调了进一步研究的必要性,以探索这种方法在 1 型糖尿病治疗中的全部潜力。所提出的方法为治疗 1 型糖尿病提供了一条前景广阔的途径,它整合了自身免疫假说、GLP-1 的增殖效应以及使用白蛋白配体的修饰作用。将这些因素结合起来,我们就能努力恢复β细胞的质量和功能,最终改善1型糖尿病患者的生活。该手稿计划于2024年进行临床试验,注册名为 "Amr Ahmed, Maher M. Akl, Semaglutide GLP1激动剂与Degludec基础胰岛素在早期1型糖尿病中的基础胰岛素",ClinicalTrials.gov识别码为NCT06057077。
{"title":"Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.\"","authors":"A. Ahmed, M. Akl","doi":"10.34172/apb.2024.040","DOIUrl":"https://doi.org/10.34172/apb.2024.040","url":null,"abstract":"This manuscript explores various aspects related to the use of dual GLP-1 agonist with degludec basal insulin as a potential treatment approach for early type 1 diabetes. The background section highlights the destruction of beta cells in type 1 diabetes and the emergence of GLP-1 agonists as a promising option for managing obesity and type 2 diabetes. The authors discuss a retrospective analysis of the efficacy of semaglutide, a GLP-1 agonist, in patients with newly diagnosed type 1 diabetes. The results show the elimination of prandial and basal insulin, increased C-peptide levels, and improved glycemic control. However, the study's retrospective nature and lack of a control group emphasize the need for larger prospective trials. The interpretation section highlights the potential of GLP-1 agonists in protecting residual beta cells, stimulating cell proliferation, and reprogramming liver cells into insulin-producing cells. Moreover, modifying GLP-1 agonists with albumin ligands shows promise in extending their half-life and enhancing their anti-diabetic effects. The perspective section provides a comprehensive overview of the synergistic approach, considering the pharmacokinetic properties of degludec, the plasticity of adult human hepatic tissue, and the benefits of modified GLP-1 derivatives. The conclusion emphasizes the need for further research to explore the full potential of this approach in type 1 diabetes treatment. The proposed approach offers a promising avenue for the treatment of type 1 diabetes, integrating the autoimmune hypothesis, the proliferative effects of GLP-1, and modifications using albumin ligands. By combining these elements, we can strive towards restoring beta cell mass and function, ultimately improving the lives of individuals living with type 1 diabetes. The manuscript is planned to undergo clinical trials in 2024, registered as 'Amr Ahmed, Maher M. Akl, Semaglutide GLP1 Agonists with Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus' with ClinicalTrials.gov Identifier NCT06057077.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140390209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advanced pharmaceutical bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1